Bacteriophage Therapy: The Solution to Antibiotic Resistance?
A special issue of Pathogens (ISSN 2076-0817).
Deadline for manuscript submissions: 28 February 2025 | Viewed by 42
Special Issue Editors
2. Bacterial Pathogenicity Laboratory, Hemato-Oncology and Research Unit, Children's Hospital of Mexico Federico Gomez/Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico
Interests: urinary tract infection; phage therapy; ESKAPE; lytic phages; multidrug resistant
Special Issue Information
Dear Colleagues,
The ESKAPE group includes six bacterial species that exhibit multidrug resistance: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. The persistent use of antibiotics has provoked the emergence of multidrug-resistant (MDR) and extensively drug resistant (XDR) bacteria, which render even the most effective drugs ineffective. The development of novel therapeutics to treat drug-resistant infections, especially those caused by ESKAPE pathogens, is needed. Alternative therapies, such as the use of bacteriophages, have been widely reported. On the other hand, urinary tract infections represent one of the most common health problems and community-acquired UTIs represent one of the most common types of infection, whose main etiological agent is Escherichia coli. UTIs are usually caused by uropathogenic E. coli (UPEC), with frequency rates of around 95% for community-acquired UTIs and 80% for uncomplicated UTIs in both inpatients and outpatients. Given the increased prevalence of multidrug-resistant UPEC strains, there is renewed interest in the use of bacteriophages as an alternative to antibiotic treatment. Phages are some of the most abundant biological entities on our planet, and they are highly versatile and adaptable to a great number of applications. Phages play major roles in the ecological balance of bacterial populations due to their ability to infect and kill bacteria in a strain-specifc manner.
Prof. Dr. José Molina-López
Dr. Edgar González-Villalobos
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ESKAPE pathogens
- drug-resistant infections
- UTI
- UPEC
- bacteriophages
- phage therapy
